|
1
|
Saidi RF and Hejazii Kenari SK: Clinical
transplantation and tolerance: Are we there yet? Int J Organ
Transplant Med. 5:137–145. 2014.PubMed/NCBI
|
|
2
|
Katabathina V, Menias CO, Pickhardt P,
Lubner M and Prasad SR: Complications of immunosuppressive therapy
in solid organ transplantation. Radiol Clin North Am. 54:303–319.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Engels EA, Pfeiffer RM, Fraumeni JF Jr,
Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly
AR, Clarke CA, et al: Spectrum of cancer risk among US solid organ
transplant recipients. JAMA. 306:1891–1901. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perez-Callejo D, Torrente M, Parejo C,
Laporta R, Ussetti P and Provencio M: Lung cancer in lung
transplantation: Incidence and outcome. Postgrad Med J. 94:15–19.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Christie JD, Edwards LB, Kucheryavaya AY,
Benden C, Dipchand AI, Dobbels F, Kirk R, Rahmel AO, Stehlik J,
Hertz M, International Society of Heart and Lung Transplantation:
The registry of the International Society for Heart and Lung
Transplantation: 29th adult lung and heart-lung transplant
report-2012. J Heart Lung Transplant. 31:1073–1086. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chapman JR, Webster AC and Wong G: Cancer
in the transplant recipient. Cold Spring Harb Perspect Med. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
7.Cohen DJ, Loertscher R, Rubin MF, Tilney
NL, Carpenter CB and Strom TB: Cyclosporine: A new
immunosuppressive agent for organ transplantation. Ann Intern Med.
101:667–682. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Penn I and Starzl TE: Immunosuppression
and cancer. Transplant Proc. 5:943–947. 1973.PubMed/NCBI
|
|
9
|
Dantal J and Soulillou JP:
Immunosuppressive drugs and the risk of cancer after organ
transplantation. N Engl J Med. 352:1371–1373. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hojo M, Morimoto T, Maluccio M, Asano T,
Morimoto K, Lagman M, Shimbo T and Suthanthiran M: Cyclosporine
induces cancer progression by a cell-autonomous mechanism. Nature.
397:530–534. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sato M, Tsujino I, Fukunaga M, Mizumura K,
Gon Y, Takahashi N and Hashimoto S: Cyclosporine a induces
apoptosis of human lung adenocarcinoma cells via caspase-dependent
pathway. Anticancer Res. 31:2129–2134. 2011.PubMed/NCBI
|
|
12
|
Brestoff JR and Artis D: Immune regulation
of metabolic homeostasis in health and disease. Cell. 161:146–160.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Calle EE and Kaaks R: Overweight, obesity
and cancer: Epidemiological evidence and proposed mechanisms. Nat
Rev Cancer. 4:579–591. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calle E, Rodriguez C, Walker-Thurmond K
and Thun MJ: Overweight, obesity, and mortality from cancer in a
prospectively studied cohort of U.S. adults. N Engl J Med.
348:1625–1638. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gonzalez MC, Pastore CA, Orlandi SP and
Heymsfield SB: Obesity paradox in cancer: New insights provided by
body composition. Am J Clin Nutr. 99:999–1005. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fonarow GC, Srikanthan P, Costanzo MR,
Cintron GB and Lopatin M; ADHERE Scientific Advisory Committee
Investigators, : An obesity paradox in acute heart failure:
Analysis of body mass index and inhospital mortality for 108,927
patients in the acute decompensated heart failure national
registry. Am Heart J. 153:74–81. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park J, Ahmadi SF, Streja E, Molnar MZ,
Flegal KM, Gillen D, Kovesdy CP and Kalantar-Zadeh K: Obesity
paradox in end-stage kidney disease patients. Prog Cardiovasc Dis.
56:415–425. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Boden G: Obesity and free fatty acids.
Endocrinol Metab Clin North Am. 37:635–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roithmaier S, Haydon AM, Loi S, Esmore D,
Griffiths A, Bergin P, Williams TJ and Schwarz MA: Incidence of
malignancies in heart and/or lung transplant recipients: A
single-institution experience. J Heart Lung Transplant. 26:845–849.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van Raemdonck D, Vos R, Yserbyt J,
Decaluwe H, De Leyn P and Verleden GM: Lung cancer: A rare
indication for, but frequent complication after lung
transplantation. J Thorac Dis. 8:S915–S924. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Katabathina VS, Menias CO, Tammisetti VS,
Lubner MG, Kielar A, Shaaban A, Mansour J, Surabhi VR and Hara AK:
Malignancy after solid organ transplantation: Comprehensive imaging
review. Radiographics. 36:1390–1407. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Testa JR and Tsichlis PN: AKT signaling in
normal and malignant cells. Oncogene. 24:7391–7393. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lawlor MA and Alessi DR: PKB/Akt: A key
mediator of cell proliferation, survival and insulin responses? J
Cell Sci. 114:2903–2910. 2001.PubMed/NCBI
|
|
26
|
Clerkin JS, Naughton R, Quiney C and
Cotter TG: Mechanisms of ROS modulated cell survival during
carcinogenesis. Cancer Lett. 266:30–36. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qin X, Li X, Liu C and Chen Z: A novel
mechanism of pre-transplant insulin resistance contributing to
post-transplant complications: Cyclosporin A-induced
O-GlcNAcylation. Biochem Biophys Res Commun. 492:172–177. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moreno-Sanchez R, Rodriguez-Enriquez S,
Marin-Hernandez A and Saavedra E: Energy metabolism in tumor cells.
FEBS J. 274:1393–1418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lenno H, Sperrin M, Badric E and Renehan
AG: The obesity paradox in cancer: A review. Curr Oncol Rep.
18:562016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Klein S and Wolfe RR: Carbohydrate
restriction regulates the adaptive response to fasting. Am J
Physiol. 262:E631–E636. 1992.PubMed/NCBI
|
|
31
|
Robbins HY and Arcasoy SM: Malignancies
following lung transplantation. Clin Chest Med. 32:343–355. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dantal J, Hourmant M, Cantarovich D, Giral
M, Blanch G, Dren B and Soulillou JP: Effect of long-term
immunosuppression in kidney-graft recipients on cancer incidence:
Randomised comparison of two cyclosporin regimens. Lancet.
351:623–628. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wimmer CD, Rentsch M, Crispin A, Illner
WD, Arbogast H, Graeb C, Jauch KW and Guba M: The janus face of
immunosuppression-de novo malignancy after renal transplantation:
The experience of the Transplantation Center Munich. Kidney Int.
71:1271–1278. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Masuo T, Okamura S, Zhang Y and Mori M:
Cyclosporine A inhibits colorectal cancer proliferation probably by
regulating expression levels of c-Myc, p21(WAF1/CIP1) and
proliferating cell nuclear antigen. Cancer Lett. 285:66–72. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kawahara T, Kashiwagi E, Ide H, Li Y,
Zheng Y, Ishiguro H and Miyamoto H: The role of NFATc1 in prostate
cancer progression: Cyclosporine A and tacrolimus inhibit cell
proliferation, migration, and invasion. Prostate. 75:573–584. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yokoyama I, Hayashi S, Sato E, Kobayashi
T, Negita M, Uchida K and Takagi H: Enhancement of tumor
proliferation by cyclosporine A in early phase of experimental
hepatic metastasis. Jpn J Cancer Res. 85:704–709. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chaikriangkrai K, Jhun HY, Graviss EA and
Jyothula S: Overweight-mortality paradox and impact of six-minute
walk distance in lung transplantation. Ann Thorac Med. 10:169–175.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
DiCecco SR and Francisco-Ziller N: Obesity
and organ transplantation: Successes, failures, and opportunities.
Nutr Clin Pract. 29:171–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Després JP and Lemieux I: Abdominal
obesity and metabolic syndrome. Nature. 444:881–887. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Flechner SM, Kolbeinsson ME, Tam J and Lum
B: The impact of body weight on cyclosporine pharmacokinetics in
renal transplant recipients. Transplantation. 47:806–810. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee J: Use of antioxidants to prevent
cyclosporine a toxicity. Toxicol Res. 26:163–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Perez de Lema G, Arribas I, Prieto A,
Parra T, De Arriba G, Rodríguez-Puyol D and Rodríguez-Puyol M:
Cyclosporin A-induced hydrogen peroxide synthesis by cultured human
mesangial cells is blocked by exogenous antioxidants. Life Sci.
62:1745–1753. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
McGrath LT, Treacy R, McClean E and Brown
JH: Oxidative stress in cyclosporin and azathioprine treated renal
transplant patients. Clin Chim Acta. 264:1–12. 1997. View Article : Google Scholar : PubMed/NCBI
|
